Dr. Mark H. Pollack named Chief Medical Officer for Myriad Neuroscience

SALT LAKE CITY, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Mark H. Pollack, M.D., chief medical officer of Myriad Neuroscience effective Jan. 15, 2020.